A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors

This study is testing a new experimental drug, BMS-986507, in combination with existing cancer treatments to see if they can better help the immune system fight advanced lung or breast cancers. The goal is to find the right dose that is safe for patients while effectively targeting tumor growth.

This study is looking for adults with certain types of advanced lung or breast cancer that can be measured on scans. Participants generally need to be active and able to perform their daily tasks, and specific gene mutation testing will be used to see if this treatment is a good fit for you.

During the study, you will receive the experimental treatment and be monitored very closely by a medical team to check for side effects and see how well the medicine is working. You will have regular check-ups and imaging tests, such as CT or MRI scans, to track your progress throughout the process.

The study is currently recruiting patients at medical centers in Birmingham, Alabama; Miami, Florida; and Iowa City, Iowa. Because it is a clinical trial, your participation helps researchers learn if these new combinations are more effective than current standard treatments.